FTC approves Gilead Sciences, Calistoga Pharmaceuticals merger
The U.S. Federal Trade Commission today granted approval to Gilead Sciences’ acquisition of Calistoga Pharmaceuticals for 375 million dollars in cash. Calistoga stands to gain an additional 225 million dollars if...To view the full article, register now.
Already a subscriber? Click here to view full article